Procter & Gamble (NYSE:PG) and Colgate-Palmolive (NYSE:CL) reported quarterly earnings in January, placing two of consumer staples’ most decorated dividend payers in sharp contrast. Procter & Gamble carries 69 consecutive years of dividend increases, while Colgate has notched 63 straight years. Both navigate tariffs, sluggish volume, and cautious consumer spending.
Procter & Gamble (PG) reported flat organic sales in Q2 FY2026 with 1% pricing offset by 1% volume decline, while facing $400M in annual tariff costs and 6.53% operating income decline despite 1.5% revenue growth.
Colgate-Palmolive (CL) posted stronger Q4 2025 with 2.2% organic sales growth and $5.23B revenue beating estimates by 2.04%, though a $919M Filorga goodwill impairment resulted in negative $0.05 GAAP EPS.
Procter & Gamble pursues large-scale restructuring with 7,000 overhead cuts and 26.16% capex growth to offset tariff drag and stabilize margins, while Colgate targets faster execution through AI analytics and its 2030 strategy, creating divergent risk-reward profiles for long-term dividend investors.
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.
Procter & Gamble’s Q2 FY2026 showed a business holding ground rather than accelerating. Organic sales came in flat, with 1% pricing offset by a 1% unit volume decline. Beauty led with 5% organic growth, and Health Care matched that pace. Baby, Feminine & Family Care weakened, where organic sales fell 4%, with Family Care down double digits.
READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks
Colgate’s Q4 2025 told a livelier top-line story. Revenue rose 5.8% year-over-year to $5.23 billion, beating estimates by 2.04%. Organic sales grew 2.2%, with 3.1% foreign exchange tailwind amplifying the headline. Hill’s Pet Nutrition contributed $1.20 billion, up 4.9%, and Africa/Eurasia surged 10.3% organically.
North America slipped 1.8% organically. The quarter carried a painful footnote: a $919 million goodwill impairment on the Filorga skin health business, driven by weak China performance, pushing GAAP EPS to -$0.05.
Business Driver | Procter & Gamble
| Colgate-Palmolive |
|---|
Revenue (Most Recent Quarter) | $22.21B | $5.23B |
Organic Sales Growth | Flat | +2.2% |
Dividend Streak | 69 years | 63 years |
Quarterly Dividend | $1.0568 | $0.53 |
Dividend Yield | 2.91% | 2.44% |
Procter & Gamble is restructuring at scale. The June 2025 portfolio and productivity plan targets up to 7,000 non-manufacturing overhead cuts by end of FY2027, and capital expenditures jumped 26.16% year-over-year in Q2. The company absorbs approximately $400 million in after-tax tariff costs this fiscal year. Operating income fell 6.53% year-over-year despite revenue rising 1.5%, as restructuring costs and tariff drag compress margins.
Colgate leans into a different reinvention. CEO Noel Wallace unveiled a 2030 strategy built around AI-driven analytics, science-based innovation, and omni-channel demand generation. The company holds a 41.2% global toothpaste market share and is exiting private-label pet food to sharpen Hill’s.
Its Strategic Growth and Productivity Program targets $200 to $300 million in cumulative pre-tax savings through 2028. Colgate is smaller and faster to pivot, though the Filorga impairment signals execution risk in premium skin care.
Strategic Lens | Procter & Gamble | Colgate-Palmolive |
|---|
Core Bet | Portfolio pruning and scale productivity | AI analytics and global brand penetration |
Growth Engine | Beauty and Health Care segments | Hill’s Pet Nutrition and emerging markets |
Key Vulnerability | Tariff drag and volume weakness | North America softness and Filorga overhang |
Trailing P/E | 21x | 32x |
For Procter & Gamble, the second half of FY2026 must deliver on Jejurikar’s promise. FY2026 guidance calls for organic sales flat to up 4% and core EPS of $6.83 to $7.09. Beauty and Health Care must carry more weight while Family Care stabilizes.
The stock trades down 12.29% over the past year, well below its 52-week high of $167.46 and analyst consensus target of $164.95.
Colgate’s FY2026 guidance targets net sales growth of 2% to 6% with gross margin expansion, which sounds credible given recent momentum. North America slipped 1.8% organically in Q4 and needs recovery for the 2030 strategy to gain traction.
Colgate is up 7.16% year-to-date versus PG’s 1.46% gain, a gap reflecting the market rewarding Colgate’s cleaner near-term narrative.
Both stocks are frequently held in defensive income portfolios given their long dividend histories. Colgate’s year-to-date performance and cleaner Q4 beat appeal to investors seeking near-term momentum. The 2030 strategy targets measurable savings and market share expansion, and Hill’s remains a growth contributor.
For a dividend-focused investor building a decade-long position, Procter & Gamble’s scale, brand depth across Tide, Pampers, Gillette, and Oral-B, and 135 consecutive years of dividend payments since 1890 represent durability Colgate cannot match.
The 2.91% yield beats Colgate’s 2.44%, and the valuation at 21x trailing earnings is more reasonable than Colgate’s 32x. The restructuring is a short-term drag, but execution could drive meaningful rerating. PG’s current discount to its 52-week high positions it as a lower-valuation option relative to its recent history for income-focused investors monitoring the restructuring timeline.
Wall Street is pouring billions into AI, but most investors are buying the wrong stocks. The analyst who first identified NVIDIA as a buy back in 2010 — before its 28,000% run — has just pinpointed 10 new AI companies he believes could deliver outsized returns from here. One dominates a $100 billion equipment market. Another is solving the single biggest bottleneck holding back AI data centers. A third is a pure-play on an optical networking market set to quadruple. Most investors haven’t heard of half these names. Get the free list of all 10 stocks here.
